Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40 results about "Glutathione Transferases" patented technology

Glutathione S Transferase (GST) is a vital enzyme, that is separate from glutathione (GSH), the master antioxidant (and the main subject of this website). GST and GSH work together in harmony to detoxify! Glutathione S Transferase (GST) is an enzyme that aids in detoxification.

Methods and kits for the diagnosis of acute coronary syndrome

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.
Owner:RULES BASED MEDICINE

Gene sequence of glutathionetransferase of vinca rosea

A vinca rosea Glutathione S-transferase gene sequences, and it coding product amino acid sequence. It relates to a kind of new gene sequence, characterized in that: this gene is 929bp, at the point of 56bp there is the start coding triplet ATG, 718bp the ending coding triplet TGA, 910bp additional signal polyA. The gene sequence has not any inner gene, 663bp completely disclosed code-reading frame, code 220 amino acid. Nucleotide sequence and Capsicum Chinese gene GST1 has reached 67.7% homeotic source, and Euphorbia esula gene GST 57.7 homeotic source. This invention also provides a method to gain a full length of forced gene. First we enrich the anti-dry expressing gene in a moderate dry condition; then we establish full length genomic library of cDNA and detecting order, obtain the anti-dry related full length forcing gene in most short period. This anti-dry gene straightly links to eukaryotes expressing carrier pCMV plasmid, detected of the order by t3, t7 primer, filtered by eukaryotes expressing. This invention distills the full length gene of glucoside peptide transferase. This gene has a good anti-oxidate function, increases express in adverse circumstance forces in the process, the gene eliminates the free radical of oxidation. This gene colon expands the gene source of plant anti-dry, and provides a more rich and good usable gene for enhancing the anti-dry function and meliorating breed.
Owner:NORTHEAST FORESTRY UNIVERSITY +1

Integrin blocking agent AP-25 expressed by modification of polyethylene glycol and protein fusion and its application

InactiveCN103819542AExtended half-lifeDoes not affect the activity in vivo and in vitroSenses disorderPeptide/protein ingredientsSequence signalHalf-life
The invention relates to the medicine field, and more specifically relates to an integrin blocking agent capable of inhibiting tumor vessel generation, having integrin element endophilicity and combination capability, the blocking agent is a polypeptide, and the polypeptide is modified by polyethylene glycol, after modifying, the half-life period of the polypeptide is prolonged, immunogenicity is reduced, and the blocking agent enables fusion expression with bovine serum albumin, heat shock protein, chaperonin, glutathione transferase (GST), signal peptide and immunoglobulin, and is in favor of correct formation of disulfide bond, the half life period can be prolonged, a certain special function of fusion protein is simultaneously increased. The integrin blocking agent polypeptide after modification and fusion expression can be used in treatment of solid tumor. The designed integrin blocking agent polypeptide has the advantages of scientific, reasonable, feasible and effective performances, and can be a treatment medicine for treating solid tumor of human, the treatment spectrum of the integrin blocking agent can be greatly developed, and the integrin blocking agent has obviously social value and market value.
Owner:CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products